Lupin Limited (Lupin) announced the launch of an authorised generic version of Horizon Pharma Therapeutics’ PENNSAID® (Diclofenac Sodium Topical Solution), 2% w/w.
In the United States, Diclofenac Sodium Topical Solution, 2% w/w (RLD PENNSAID®) had an anticipated annual sales of USD 509 million.
Lupin is a worldwide pharmaceutical firm based in Mumbai, India that focuses on innovation. The Company develops and commercialises a diverse variety of branded and generic formulations, biotechnology products, and APIs in over 100 markets worldwide, including the United States, India, South Africa, and Asia Pacific (APAC), Latin America (LATAM), Europe, and the Middle East.
The company is a market leader in the cardiovascular, anti-diabetic, and respiratory segments, and it also has a substantial presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women’s health segments. Lupin is the third-largest pharmaceutical firm in the United States in terms of prescriptions.